I want to renew
2019/12/31 15:16:41 Source: China Securities Journal CSI 2019/12/31 15:16:41
With the involvement of the regulator,
In this regard, analysts pointed out that in the debt repayment plan proposed by Weiming Group, the medical assets involved are mostly in the early clinical stage, and there is a large uncertainty as to whether it can be successfully marketed in the future. In addition, the true value of biological assets is also worthy of attention. Whether such a debt service plan can pass the final decision depends on the voting results of the shareholders' meeting held on January 17, 2020.
According to the announcement, after the company's self-examination and verification with Weiming Group, from December 2017 to June 2019, Weiming Group occupied Xiamen Weiming Biomedical Co., Ltd., a wholly-owned subsidiary of the company (hereinafter referred to as "Xiamen Weiming") The balance of its own funds of Tianjin Weiming Biopharmaceutical Co., Ltd. and its subsidiary Tianjin Weiming (hereinafter referred to as "Tianjin Weiming") totaled 507 million yuan. As of December 31, 2019, the balance of non-operating occupation funds was 507 million yuan, and interest was 54.357 million yuan.
The above violations did not fulfill the corresponding review procedures and information disclosure obligations in accordance with the regulations.
The announcement said that because the Weiming Group was involved in multiple economic dispute lawsuits and had difficulty in liquidity, it was unable to repay the funds occupied by the company in cash. The Weiming Group repaid the funds of the listed company it occupied with its assets. The assets used for debt repayment include two parts: one of the four drugs in the early clinical stage, namely recombinant anti-TNFα fully humanized monoclonal antibody injection, recombinant anti-CD52 humanized monoclonal antibody injection, and recombinant injection The anti-CD25 human and mouse chimeric monoclonal antibody and the recombinant anti-CD3 humanized monoclonal antibody injection were used to offset the funds occupied by the Weiming Group. After evaluation, the total value of these four pharmaceutical technologies was 118 million yuan. The other part is the 100% equity of Jilin Weiming Tianren Chinese Medicinal Materials Technology Development Co., Ltd. (hereinafter referred to as “Jilin Weiming”) owned by Weiming Group.
According to the announcement, Jilin's unnamed core assets are its four undergrowth ginseng productive biological assets, which are mainly 2.43.4 million undergrowth American ginseng and undergrowth ginseng, and the ginseng age is 9-17 years. Jilin has not planted ginseng under the name, has not carried out other businesses, and has no long-term or short-term loans and other debts. After evaluation, the evaluation value was 2.205 billion yuan. The Ministry of Agriculture's Special Economic Animal, Plant, and Product Quality Supervision, Inspection and Testing Center re-evaluated the company's four productive biological assets.
Announcement shows that the above two parts of debt assets have been transferred to
"This transaction constitutes a related party transaction and is a major issue for the company. It should be performed in accordance with the relevant procedures and disclosed in a timely manner." On December 31, a person from an A-share listed company who declined to be named pointed out
In view of the fairness and letter compliance of the above non-cash asset transactions,